Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants
{{output}}
The treatment of urothelial cancer (UC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICIs). However, while ICIs have achieved better therapeutic results than traditional chemotherapeutic agents, immune-related adverse events (ir... ...